Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

20.54
+0.14000.69%
Post-market: 20.30-0.2357-1.15%19:30 EDT
Volume:1.06M
Turnover:21.53M
Market Cap:1.32B
PE:-5.92
High:20.71
Open:20.38
Low:19.64
Close:20.40
52wk High:23.19
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.96
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:4.11
PE(LYR):-5.52

Loading ...

Cullinan Therapeutics Inc -Cln-978 Shows Favorable Safety Profile With Single Target Doses up to 30 ΜG as Well as Initial Multi-Dose Regimen

THOMSON REUTERS
·
Jun 06

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

GlobeNewswire
·
Jun 06

Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors

TIPRANKS
·
Jun 06

Cullinan Therapeutics to present initial multi-dose clinical data for CLN-978 in rheumatoid arthritis study

Reuters
·
May 26

Stifel Nicolaus Reaffirms Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
May 25

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM)

TIPRANKS
·
May 20

Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street

TIPRANKS
·
May 20

Cullinan Therapeutics wins FDA orphan drug designation for CLN-049 in relapsed AML

Reuters
·
May 19

Cullinan Therapeutics Receives FDA Orphan Drug Designation for Cln-049, a Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

THOMSON REUTERS
·
May 19

Cullinan Therapeutics Price Target Maintained With a $38.00/Share by BTIG

Dow Jones
·
May 19

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Cullinan Management (CGEM)

TIPRANKS
·
May 19

Cullinan presents initial Phase 1 CLN-978 data in refractory RA, SLE at EULAR 2026

Reuters
·
May 19

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

GlobeNewswire
·
May 19

AnaptysBio names Christopher Murphy as CFO

Reuters
·
May 11

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 11

Cullinan Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
May 08

Cullinan Therapeutics price target raised to $37 from $36 at Wedbush

TIPRANKS
·
May 08

Analysts’ Top Healthcare Picks: Cullinan Management (CGEM), Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
May 08

Cullinan Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate

Benzinga Earnings
·
May 07